1 To investigate possible mechanisms underlying the ability of combined administration of a 5-hydroxytryptamine 2 (5-HT 2 ) antagonist and a thromboxane A 2 antagonist to reduce reperfusion-induced arrhythmias, the eects of these drugs alone and in combination on platelet aggregation and on cardiac muscle were determined. 2 Platelet aggregation was measured in whole blood obtained from anaesthetized rats. Concentrations of 5-HT (10 mM) and the thromboxane A 2 mimetic U46619 (1 mM) which did not cause aggregation themselves, enhanced the responses to ADP (0.1 mM) and to collagen (1 mg ml 71
O in control). The greatest reduction of platelet aggregation was seen in blood from rats which had received both antagonists, with the response to U46619 plus 5-HT plus collagen being 2.7+ 0.6 O compared to 14.2+1.7 O in controls. In contrast, there was no signi®cant attenuation of platelet aggregation in blood from rats which had received the lower doses of each antagonist alone. Only the combination of ICI 170,809 (0.3 mg kg 71 ) and ICI 192,605 (0.3 mg kg 71 min
71) reduced the response to U46619 plus 5-HT plus collagen (7.6+1.4 O versus 15.0+0.5 O in controls). 5 In rat isolated ventricular muscle preparations, ICI 170,809 increased the eective refractory period; e.g. from 39+4 to 86+18 ms, 10 min after adding 30 mM to left papillary muscles. ICI 192,605 did not increase the eective refractory period itself and did not alter the ability of ICI 170,809 to prolong the eective refractory period. In the presence of 100 mM ICI 192,605, ICI 170,809 (30 mM) increased the eective refractory period from 38+7 to 100+30 ms. 6 These results indicate that the previously observed antiarrhythmic activity of combined administration of the higher doses of ICI 170,809 and ICI 192,605 is unlikely to be due to direct eects on cardiac muscle but could be a consequence of reduced platelet aggregation.